Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 4/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230872 | 0.95 | ALDH1A1 (0.40) | ALDH1A1SRCLMNAPRKDCTSHR | |
| SCHEMBL6904874 | 0.90 | CA1 (0.32) | ALDH1A1LMNACA1CA2DRD2 | |
| SCHEMBL2871507 | 0.86 | SRC (0.52) | ALDH1A1SRCLMNAPRKDCKDM4E | |
| SCHEMBL5179449 | 0.84 | LMNA (0.42) | ALDH1A1LMNATSHRKDM4EERN1 | |
| SCHEMBL5042411 | 0.81 | ALDH1A1 (0.33) | ALDH1A1TSHRKDM4ECA1CA2 | |
| SCHEMBL6906689 | 0.80 | MEN1 (0.40) | ALDH1A1TSHRKDM4ECA1MAPT | |
| SCHEMBL1337920 | 0.80 | F2R (0.39) | ALDH1A1LMNAPRKDCTSHRKDM4E | |
| SCHEMBL9906779 | 0.79 | ALOX5AP (0.35) | ERN1CA1CA2 | |
| SCHEMBL6907417 | 0.78 | PREP (0.32) | ALDH1A1CA1 | |
| SCHEMBL13876764 | 0.78 | KCNJ1 (0.34) | ALDH1A1LMNACA1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200297658-A1 | Compositions and Methods for Treatment of Cancer | TERMAN DAVID S (US) | 2020-09-24 | — | — | US | disclosed |
| EP-1601348-A4 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7078552-B2 | Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs | ARIZONA BOARD OF REGENTS (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1278758-A4 | COMBRETASTATIN A-1 PHOSPHATE AND COMBRETASTATIN B-1 PHOSPHATE PRODRUGS | UNIV ARIZONA STATE (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030220298-A1 | Combrestatin a-1 phosphate and combrestatin b-1 phosphate prodrugs | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2003-11-27 | — | — | US | disclosed |
| EP-1278758-A1 | COMBRETASTATIN A-1 PHOSPHATE AND COMBRETASTATIN B-1 PHOSPHATE PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081355-A1 | COMBRETASTATIN A-1 PHOSPHATE AND COMBRETASTATIN B-1 PHOSPHATE PRODRUGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA,ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2001-11-01 | — | — | WO | disclosed |
| US-5569786-A | ANTICARCINOGENIC AGENTS, LEUKEMIA | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5409953-A | Administering to treat lymphocytic leukemia | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0276051-B1 | ANTINEOPLASTIC COMPOUNDS | ARIZONA BOARD OF REGENTS (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0276051-A2 | Antineoplastic compounds | ARIZONA BOARD OF REGENTS (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297658-A1 | Compositions and Methods for Treatment of Cancer | CD47, VEGFA, VHL | ALDH1A1 4444/4885SRC 1173/4885LMNA 578/4885 |
| US-20030220298-A1 | Combrestatin a-1 phosphate and combrestatin b-1 phosphate prodrugs | APRT, TYMP, PCYT1A | ALDH1A1 1586/4885SRC 3293/4885LMNA 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.